Daratumumab, a first in class human monoclonal antibody targeting CD38, is active and well tolerated as a single agent [1,2] and in combination with standards-of-care in both newly diagnosed [3,4,5] and relapsed/refractory multiple myeloma (MM) patients [6,7,8]. This evidence concerns the gene CD38 and Miyoshi myopathy.